ARTICLE | Company News
Agalimmune, BioLineRx deal
March 31, 2017 7:45 PM UTC
BioLineRx acquired cancer company Agalimmune for $3 million in cash and $3 million in BioLineRx shares up front, plus undisclosed milestones. Agalimmune's lead compound AGI-134 is slated to begin clin...